Under the Medicines Australia agreement, PBAC considered an immediate change to the discount rate with implementation planned through updated guidelines from July 2022. That change never arrived. The committee opposed any reduction. Surely that prejudices any role for the committee in the new review. Yes, a new review.
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News


